Clinical Trial Update: Pemetrexed and Gemcitabine Every 14 Days Versus Every 21 Days in Advanced Non Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial compared pemetrexed plus gemcitabine on 14-day vs 21-day schedules in advanced non-small-cell lung cancer. The study was terminated, with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)
• Gemzar (gemcitabine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Non-Small-Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2009-05-14